ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjögren’s syndrome"

  • Abstract Number: 2190 • ACR Convergence 2023

    Saliclick: A Novel Technology for Minimal Invasive Salivary Gland Biopsy in Suspected Sjögren’s Syndrome

    Thomas Hügle1, Diana Dan2 and Alexandre Dumusc3, 1Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland, 2Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, 3Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Switzerland, Lausanne, Switzerland

    Background/Purpose: Labial minor salivary gland (MSG) biopsy is a major element in the diagnosis of Sjögren´s Syndrome and the exclusion of other pathologies, respectively. Transient…
  • Abstract Number: 0802 • ACR Convergence 2023

    Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells

    Samuel Kemble1, Christopher Mahony2, Charlotte Smith2, Joel Rurik3, Haig Aghajanian3, Jonathan Epstein3, Mark Coles4 and Adam Croft2, 1University Birmingham, Rugeley, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3University of Pennsylvania, Philadelphia, PA, 4University of Oxford, Oxford, United Kingdom

    Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…
  • Abstract Number: 1374 • ACR Convergence 2023

    Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival

    Marco Sprecher1, Florine Weber2, Kastriot Kastrati3, Helmut Prosch4, Natasha Moe5, Emily Langballe6, Cosimo Bruni7, Oyvind Molberg8, Phuong Phuong Diep9, Christian Clarenbach10, Paul Studenic11, Helena Andersson8, Oyvind Midtvedt12, Torhild Garen8, Karoline Lerang13, Thomas Frauenfelder14, Helga Radner15, Oliver Distler7 and Anna Maria Hoffmann-Vold16, 1Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 2Dept of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 3Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, 4Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, 5Dept of Radiology, University Hospital Oslo, Oslo, Norway, 6Universitetet i Oslo, Oslo, Norway, 7Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, 9Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, 10Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 11Medical University of Vienna and Karolinska Institutet (sweden), Vienna, Austria, 12Oslo University Hospital, Oslo, Norway, 13Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 14Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 15Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 16Oslo University Hospital, Department of Rheumatology, Oslo, Norway

    Background/Purpose: Interstitial lung disease (ILD) has been reported to be present in 10-15% of patients with primary Sjögren's syndrome (pSS). Knowledge on risk factors predicting…
  • Abstract Number: 1771 • ACR Convergence 2023

    Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases

    Verónica Pulito-Cueto1, David Iturbe-Fernández2, Victor Mora-Cuesta2, Joao Carlos Batista-Liz1, Belén Atienza-Mateo3, María Sebastián-Mora1, Virginia Portilla1, Alfonso Corrales1, Miguel A Gonzalez-Gay4, Jose Cifrian5, Ricardo Blanco1 and Raquel López-Mejías1, 1Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 2Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, 3Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, 5Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain

    Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…
  • Abstract Number: 2191 • ACR Convergence 2023

    Efficacy of anti-CD38 Treatment with Daratumumab in Two Cases of Refractory and Severe Sjogren Disease

    Gaetane Nocturne1, Mathilde di Filippo2, Oriane Marmontel2, Pascale Chretien1, Roman Krzysiek1, François Lifermann3, Nawal Rahal1, Rakiba Belkhir4, Philippe Moulin2 and Xavier Mariette5, 1APHP, Le Kremlin-Bicêtre, France, 2Hospices Civils de Lyon, Lyon, France, 3Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France, 4Rheumatology Department, Université Paris-Saclay, INSERM U1184, Hôpital Bicêtre, APHP, FHU CARE, Le Kremlin-Bicêtre, France, 5Université Paris-Saclay, Le Kremlin-Bicêtre, France

    Background/Purpose: Sjögren's disease (Sjo) is a systemic autoimmune disease. In 80% of the patients, Sjo is responsible for dryness, fatigue, and joint pain. In 10%…
  • Abstract Number: 1219 • ACR Convergence 2023

    Patient Experience of Brain Fog to Inform the Development of a De Novo Patient Reported Outcome (PRO) in Patients with Sjögren’s Disease

    Denise Kruzikas1, Ann Eldred2, Shelly Kafka3, Janet Church4, Katherine Hammitt4, Patricia Koochaki5 and Christina O'Donnell6, 1AbbVie, Inc., North Chicago, IL, 2AbbVie, Inc., Lake Bluff, IL, 3AbbVie, Inc., Norristown, PA, 4Sjögren’s Foundation, Reston, VA, 5ICON Clinical Research LLC, Raleigh, NC, 6ICON plc, Raleigh, NC

    Background/Purpose: Brain fog is commonly reported by SJD patients, though limited evidence exists to understand patient experiences. Various terms may be used to describe brain…
  • Abstract Number: 1375 • ACR Convergence 2023

    The Relative Burden of Fatigue Is Associated with High TSH/fT4 Ratio in Korean Patients with Primary Sjogren’s Syndrome

    Jee-in Lee1, Se Rim Choi2, You-Jung Ha2, Eun Ha Kang3, Keun-Suh Kim4, Joon Young Hyon5 and Yun Jong Lee6, 1Seoul National University of Bundang Hospital, Seongnam, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnamsi, South Korea, 3Seoul National University Bundang Hospital, Seongnam, South Korea, 4Department of Periodontology, Section of Dentistry, Seoul National University Bundang Hospital, Seongnamsi, South Korea, 5Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnamsi, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea

    Background/Purpose: To investigate the prevalence of anti-thyroid autoantibodies, abnormal thyroid function, and their clinical impacts in Korean patients with primary Sjögren's syndrome (pSS). Methods: One…
  • Abstract Number: 2041 • ACR Convergence 2023

    An Analysis of Recurrent Parotitis Patients Referred to Rheumatology Clinic

    Yiressy Pina1, Elton Lambert2, Maria Pereira2 and Marietta De Guzman2, 1Baylor College of Medicine, Richmond, TX, 2Baylor College of Medicine, Houston, TX

    Background/Purpose: Juvenile recurrent parotitis (JRP) is characterized by non-obstructive, non-suppurative inflammation of the parotid glands of unknown etiology. The onset of symptoms occurs typically between…
  • Abstract Number: 2192 • ACR Convergence 2023

    New Inducible Mouse Model of Sjögren’s Syndrome Represents a Valuable Tool to Assess the Impact of Gene Knockout on the Disease’s Physiopathology

    Dorian Parisis1, Nargis Bolaky2, Anissa Benchehida2, Christoph Küper3, jason Perret2, Muhammad Soyfoo1 and Christine Delporte2, 1Hôpital Universitaire de Bruxelles - Hôpital Erasme, Brussels, Belgium, 2Faculté de médecine - Université Libre de Bruxelles, Brussels, Belgium, 3Institute for Molecular Medicine, MSH Medical School Hamburg, Hamburg, Germany

    Background/Purpose: Primary Sjögren's syndrome (pSS) is a chronic rheumatic disease characterized by lymphocytic infiltration of exocrine glands, resulting in sicca syndrome with extra-glandular autoimmune features.…
  • Abstract Number: 1220 • ACR Convergence 2023

    Sjögren’s Patients’ Experiences and Content Validity of the Dry Eye Disease Symptom Questionnaire (DED-SQ)

    Denise Kruzikas1, Ann Eldred2, Shelly Kafka3, Janet Church4, Katherine Hammitt4, Patricia Koochaki5 and Christina O'Donnell6, 1AbbVie, Inc., North Chicago, IL, 2AbbVie, Inc., Lake Bluff, IL, 3AbbVie, Inc., Norristown, PA, 4Sjögren’s Foundation, Reston, VA, 5ICON Clinical Research LLC, Raleigh, NC, 6ICON plc, Raleigh, NC

    Background/Purpose: Dry eye is one of the most important and prevalent symptoms experienced by patients with Sjögren's Disease (SJD). The DED-SQ is a 12-item patient…
  • Abstract Number: 1376 • ACR Convergence 2023

    SJOGRENSER Registry: Prospective Evaluation of a Cohort of Patients with Primary Sjögren’s Syndrome After 8 Years of Follow-up

    Mónica Fernández-Castro1, Zulema Plaza2, Jose Rosas3, Victor Martinez-Taboada4, Alejandro Olivé5, Raúl Menor-Almagro6, SARA MANRIQUE7, Ruth López-González8, Celia Erausquin9, Antonio Naranjo9, Rocío Caño-Alameda10, Silvia Gómez-Sabater10, Jesús Alberto García Vadillo11, Belen Serrano Benavente12, Sheila Melchor13, Paula V. Estrada-Alarcón14, Angel Garcia-Aparicio15, Cristina Bohorquez16, Enrique Júdez17, Ximena Larco18, Javier Loricera19, Nerea Alcorta Lorenzo20, Beatriz Paredes Romero21, Jorge González Martín22, María Ángeles Blázquez Cañamero23, Consuelo Ramos-Giráldez24, Fernando Alonso25, Marta Domínguez26 and Jose Luis Andreu-Sánchez27, 1Rheumatology Department Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain, 2Universidad Autónoma de Madrid, Madrid, Spain, 3Hospital Marina Baixa, Alicante, Spain, 4Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, 5Rheumatology Department Hospital Germans Trias i Pujol, Badalona, Spain, 6Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, 7Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, 8Rheumatology Department Hospital Virgen de la Concha, Zamora, Spain, 9Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, 10Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, 11Rheumatology Department Hospital de la Princesa, Madrid, Spain, 12Rheumatology Department Hospital Gregorio Marañón, Madrid, Spain, 13Rheumatology Department Hospital Doce de Octubre, Madrid, Spain, 14Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, 15Hospital Universitario de Toledo, Toledo, Spain, 16Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, 17Rheumatology Department Hospital de Albacete, Albacete, Spain, 18Rheumatology Department Hospital de León, León, Spain, 19Hospital Universitario Marqués de Valdecilla, Santander, Spain, 20University Hospital Donostia, San Sebastian, Spain, 21Rheumatology Department Hospital Infanta Sofía, San Sebastian de los Reyes, Spain, 22Rheumatology Department Hospital Madrid Norte Sanchinarro, Madrid, Spain, 23Rheumatology Department Hospital Ramon y Cajal, Madrid, Spain, 24Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, 25Spanish Society of Rheumatology, Madrid, Spain, 26Sociedad Española de Reumatología, Madrid, Spain, 27Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain

    Background/Purpose: Describe the evolution of patients with Sjögren's syndrome (SS) in relation to the appearance of new systemic manifestations and disease activity, as well as…
  • Abstract Number: 2177 • ACR Convergence 2023

    Characterization of Crevicular Fluid Microbiota in Primary Sjögren’s Syndrome

    Gabriela Hernandez-Molina1, Alberto Lopez-Reyes2, Carlos Hernandez-Hernandez3, Vanessa Ruiz3, Amaya Llorente-Chavez4, Vanessa Saavedra-González4, Luis llorente4 and Gabriela Martínez-Nava2, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Laboratorio de Gerociencias, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City, Mexico, 3Servicio Dental. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: To describe the taxonomic composition of the microbiota in the crevicular fluid of patients with primary Sjögren's syndrome (PSS), and to assess their association…
  • Abstract Number: 2193 • ACR Convergence 2023

    Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement

    Augusto Silva1, Filipa Costa2, Mariana Silva2, Giovanni Fulvio3, Matilde Bandeira2, Manuel Silvério-António4, Nikita Khmelinskii2, Chiara Baldini3 and Vasco Romão2, 1Santa Maria Hospital, Maceira, Portugal, 2Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, 3University of Pisa, Pisa, Italy, 4Hospital Santa Maria, Lisboa, Portugal

    Background/Purpose: Extraglandular manifestations may occur in up to 40-50% of patients with SS, including inflammatory arthralgia and chronic polyarthritis (1-3). ACPA are prototypical markers of…
  • Abstract Number: 1245 • ACR Convergence 2023

    Evaluating a Diagnostic Algorithm for Childhood Sjögren’s Disease

    Sara Stern1, Matthew Basiaga2, Linda Amoafo1, Seunghee Cha3, Akaluck Thatayatikom4, Erin Treemarcki1, Rachel Randell5, Brian Dizon6, Jamie Diianni7, Sharon Tiger8, Janet Orrock9, Simone Appenzeller10, Cuoghi Edens11 and Scott Lieberman12, 1University of Utah School of Medicine, Salt Lake City, UT, 2Mayo Clinic, Rochester, MN, 3Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry and Center for Orphaned Autoimmune Disorders (COAD), Gainesville, FL, 4AdventHealth for Children, Orlando, FL, Orlando, FL, 5Duke University School of Medicine, Durham, NC, 6National Institute of Arthritis and Musculoskelatal and Skin Diseases, Bethesda, MD, 7Childhood Arthritis and Rheumatology Research Alliance (CARRA), Washington, DC, 8Childhood Arthritis and Rheumatology Research Alliance (CARRA), Beltsville, MD, 9The University of Texas at Austin Dell Medical School, Austin, TX, 10UNICAMP, Campinas, Brazil, 11University of Chicago, Chicago, IL, 12University of Iowa Carver College of Medicine, Iowa City, IA

    Background/Purpose: There are no widely accepted diagnostic or classification criteria for childhood Sjögren's disease (cSjD). To address the urgent need for consensus, the Childhood Arthritis…
  • Abstract Number: 1377 • ACR Convergence 2023

    Characterization of Pulmonary Manifestations of Sjögren Syndrome: A Multicenter Retrospective Study

    Loïc Meudec1, Cindy Marques2, Pierre-Antoine Juge3, Robin Dhote4, Anne-Laure Fauchais5, Emanuelle Dernis6, Olivier Vittecoq7, Alain SARAUX8, Jacques-Eric Gottenberg9, Eric Hachulla10, Véronique Le Guern11, Philippe Dieudé12, Marie-Pierre Debray13, Antoine Beurnier14, Raphaele Seror15, Xavier Mariette16 and Gaetane Nocturne17, 1CHU Kremlin-Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France, 2CHU Pitié Salpétrière, Internal Medicine 1, Paris, France, 3Division of Rheumatology, Inflammation, and Immunity Brigham & Women’s Hospital, Boston, MA, 4Department of Internal Medicine, Centre Hospitalier Avicenne, Bobigny, France, 5Dupuytren Hospital, Limoges, France, 6CH Le Mans, Le Mans, France, 7CHU Rouen, Rheumatology, Rouen, France, 8CHU Brest, Brest, France, 9Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, 10CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, 11APHP Hôpital Cochin, Paris, France, 12Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, 13CHU Bichat, Radiology, Paris, France, 14CHU Kremlin-Bicêtre, Functional Explorations, Le Kremlin-Bicêtre, France, 15University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 16Université Paris-Saclay, Le Kremlin-Bicêtre, France, 17APHP, Le Kremlin-Bicêtre, France

    Background/Purpose: Sjögren disease (Sjo) is a systemic immune-related disease with pulmonary manifestations occurring in up to 16% of patients [1], including interstitial lung disease (SS-ILD)…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology